Company intelligence / Profile preview
Heidelberg ImmunoTherapeutics
Heidelberg, Baden-Württemberg, Germanyhditx.de ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
HDIT101 has completed Phase I studies demonstrating safety and tolerability at high doses. Two independent Phase II studies are ongoing/completed:
- MATCH‑1 trial evaluates topical application for chronic recurrent orolabial HSV‑1 infection.
- MATCH‑2 trial investigates intravenous administration in chronic recurrent genital HSV‑2 infection. Both trials have completed enrollment; final results are pending analysis. Early data show good safety profile with no serious adverse events reported in healthy volunteers during dose escalation.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodiesAntibody-based immunotherapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Heidelberg ImmunoTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heidelberg ImmunoTherapeutics.